Folic Acid Interferes With Radiation Esophagitis

Inclusion Criteria:

1. Patients with malignant lung cancer (incluedig Non-small cell lung cancer, small celllung cancer) diagnosed by histopathology or cytology.
2. TNM Stage N2~N3 (IASLC International TNM staging standard for Lung Cancer, 8thedition) was indicated by radiotherapy and the patients were treated for the firsttime.
3. Aged between 18 and 75 years old,no limit on the gender.
4. ECOG≤2 or KPS≥70.
5. No contraindication of Concurrent chemoradiotherapy.
6. Patients without important organ dysfunction,hematology: it is within the normal rangeaccording to the standards of each laboratory; Cardiac function: normal range; Liverfunction: normal range; Renal function: normal range; Pulmonary function: FEV1 > 50%,mild to moderate impairment of pulmonary function.
7. Patients with good compliance to treatment received and follow-up.

Exclusion Criteria:

1. Prior to treatment, there were other esophageal diseases, such as gastrointestinalulcer, reflux esophagitis, cardia relaxation.
2. Patients with severe nutritional anemia prior to treatment.
3. The IV stage patients with uncontrolled malignant pleural effusion,with diffuse liveror lung metastasis which lead to liver or pulmonary dysfunction.
4. Patients with severe heart, lung or kidney diseass,such as uncontrolled hypertension,diabetes, unstable angina, a history of myocardial infarction or heart failure, oruncontrolled arrhythmias; There is clearly clinically diagnosed heart valve disease;The active phase of a bacterial, fungal, or viral infection; Mental disorders;Severely impaired lung function.
5. A history of previous tumors complicated with other malignant tumors.
6. The pregnant or breast-feeding patients.
7. Patients with mental and neurological diseases.